Targeting androgen receptor signaling to enhance cancer immunotherapy
Open Access
- 3 December 2025
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 47 (11) , 1252-1267
Abstract
No abstract availableKeywords
Funding Information
- Conquer Cancer Foundation (2025YIA-5518089270)
- American Society of Clinical Oncology
- National Cancer Institute (F32 CA298657)
- National Cancer Institute (RO1CA271168)
This publication has 115 references indexed in Scilit:
- Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyAnnals of Oncology, 2025
- Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyAnnals of Oncology, 2025
- Aging and androgens: Physiology and clinical implicationsReviews in Endocrine and Metabolic Disorders, 2022
- Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factorsCancer, 2022
- A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast CancerThe Oncologist, 2020
- Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical TrialsJAMA Network Open, 2020
- Sex differences in vaccine-induced humoral immunitySeminars in Immunopathology, 2018
- Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN StudyThe Prostate, 2016
- T cells localized to the androgen‐deprived prostate are TH1 and TH17 biasedThe Prostate, 2011
- Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic miceThe Prostate, 2010